Oncolytics Biotech, Pelareorep, Hepatocellular Carcinoma, HCC, Liver Cancer, Tumor Microenvironment, Immunotherapy, Cancer Immunotherapy, CD8 T Cells, PD-L1, ICOSL, Checkpoint Inhibitors,

SAN DIEGO — September 29, 2026 Oncolytics Biotech Inc. announced the publication of preclinical data supporting pelareorep’s ability to...